Published in World J Gastroenterol on August 28, 2013
Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res (2014) 1.03
Hepatic iron overload and hepatocellular carcinoma. Liver Cancer (2014) 0.92
MicroRNAs in the Evaluation and Potential Treatment of Liver Diseases. J Clin Med (2016) 0.80
Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocell Carcinoma (2014) 0.80
Comparison of percutaneous microwave ablation and laparoscopic resection in the prognosis of liver cancer. Int J Clin Exp Pathol (2015) 0.77
Influence of adriamycin on changes in Nanog, Oct-4, Sox2, ARID1 and Wnt5b expression in liver cancer stem cells. World J Gastroenterol (2014) 0.76
miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Am J Transl Res (2016) 0.75
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2008) 37.16
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Switching from repression to activation: microRNAs can up-regulate translation. Science (2007) 17.00
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med (1991) 16.01
microRNA functions. Annu Rev Cell Dev Biol (2007) 15.74
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51
pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A (1983) 8.41
Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 8.33
Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci U S A (2007) 7.93
A role for the P-body component GW182 in microRNA function. Nat Cell Biol (2005) 7.54
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell (2008) 6.58
Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J (2007) 6.26
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol (2012) 5.60
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci U S A (1979) 4.98
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol (2008) 4.76
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology (2010) 4.72
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell (2009) 4.48
MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology (2009) 4.36
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Epidemiology of hepatocellular carcinoma. Clin Liver Dis (2005) 4.29
Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem (2006) 4.15
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene (2008) 4.11
MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res (2009) 3.83
Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med (1985) 3.73
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
Molecular mechanisms of hepatocellular carcinoma. Hepatology (2008) 3.51
miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis (2009) 3.45
MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol (2007) 3.38
Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology (2010) 3.37
Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet (2005) 3.28
Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol (2010) 3.27
Biochemistry of oxygen toxicity. Annu Rev Biochem (1989) 3.26
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res (2008) 3.16
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 3.16
Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology (2011) 3.05
Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr (2008) 2.98
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One (2009) 2.97
Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology (2009) 2.96
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett (2008) 2.81
miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol (2008) 2.61
ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep (2002) 2.61
MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology (2009) 2.57
Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett (2009) 2.40
TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene (2009) 2.33
The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest (2011) 2.30
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28
Heme is involved in microRNA processing. Nat Struct Mol Biol (2006) 2.27
Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci (2009) 2.23
MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology (2009) 2.17
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16
miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One (2010) 2.15
Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology (2012) 2.12
Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr (1993) 2.06
miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis. J Hepatol (2009) 2.03
Hereditary spherocytosis with secondary haemochromatosis. Lancet (1968) 2.00
The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol (2010) 2.00
MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun (2010) 1.92
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84
MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology (2010) 1.82
MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology (2009) 1.79
MicroRNAs and the regulation of fibrosis. FEBS J (2010) 1.79
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci U S A (2011) 1.78
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc Natl Acad Sci U S A (2002) 1.77
Iron homeostasis, oxidative stress, and DNA damage. Free Radic Biol Med (1997) 1.76
Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett (2001) 1.68
Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol (2012) 1.63
Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol (2009) 1.63
Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol (2011) 1.62
MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res (2010) 1.61
MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology (2008) 1.60
Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb Symp Quant Biol (2006) 1.56
Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol (2004) 1.53
miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun (2008) 1.53
Long non-coding RNA in cancer. Int J Mol Sci (2013) 1.52
The role of microRNAs in liver cancer progression. Br J Cancer (2010) 1.52
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J (2009) 1.52
Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun (2011) 1.52
Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology (2012) 2.12
Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest (2004) 1.88
NF-kappaB regulation: the nuclear response. J Cell Mol Med (2009) 1.27
Defective bone morphogenic protein signaling underlies hepcidin deficiency in HFE hereditary hemochromatosis. Hepatology (2010) 1.05
Tauroursodeoxycholic acid inhibits apoptosis induced by Z alpha-1 antitrypsin via inhibition of Bad. Hepatology (2007) 0.95
Long noncoding RNAs in liver cancer: what we know in 2014. Expert Opin Ther Targets (2014) 0.86
Variant in CD209 promoter is associated with severity of liver disease in chronic hepatitis C virus infection. Hum Immunol (2010) 0.84
Transforming growth factor beta-1 and interleukin-17 gene transcription in peripheral blood mononuclear cells and the human response to infection. Cytokine (2010) 0.83
Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer. Cytokine (2013) 0.81
Hemochromatosis: as a conformational disorder. Int J Biochem Cell Biol (2009) 0.80
Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h. Eur J Gastroenterol Hepatol (2010) 0.79
Mortality in humans with pneumonia and sepsis is related to an uncompensated anti-inflammatory response to infection. Arch Intern Med (2008) 0.78
Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin. Eur J Gastroenterol Hepatol (2011) 0.78
Greater trochanteric hip pain. Orthop Nurs (2014) 0.77
Hemochromatosis protein HFE C282Y conformational considerations. Hepatology (2010) 0.75
Tauroursodeoxycholic acid: relieving the pathogenesis of HFE C282Y hereditary hemochromatosis. Hepatology (2008) 0.75
Semitendinosus muscle fatty infiltration following tendon harvest in rabbits. J Orthop Res (2013) 0.75